- BGI Launches the Latest Desktop Sequencer BGISEQ-50
- International Science Community Welcomes China National GeneBank Opening
- BGI and Clearbridge BioMedics Partner to Develop China CTC Liquid Biopsy Market towards Precision Medicine
- Tadataka Yamada, M.D., Former President of Global Health Program at Bill & Melinda Gates Foundation, Former Chairman of R&D at GlaxoSmithKline, Joins BGI
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- The Evolution of Chronic Lymphocytic Leukemia Revealed
- BGI involved in publication of the first seahorse genome in Nature
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
- Mapping more genomes will create a healthcare 'big data revolution'
Tel: +86-755-36307212Email: email@example.com
One of world’s leading genomics organizations and UW Medicine sign Memorandum of Understanding to advance biomedical technology
May 11, 2016, Shenzhen, China, Seattle, America -- BGI, one of the world’s largest genomics organizations, and UW Medicine have signed a Memorandum of Understanding to collaborate on biomedical technology development. The shared aim is to advance precision medicine for diagnosis, treatment and prevention of common and rare diseases. BGI is headquartered in Shenzhen, Guangdong, China.
The relationship between BGI and UW Medicine will create opportunities for physicians, scholars and students to cooperate in scientific and medical discovery.
The research and educational collaboration will look particularly at applying next-generation sequencing to improve the health of communities, through population genetics and personalized healthcare.
The work also will include data collection, storage, international sharing and analysis of omics data. Omics refers to the pool of biological molecules – DNA, proteins, metabolites – that affect the structure and function of living things.
BGI is an international leader in pursuing the vision of using genomics to benefit humanity. It has made many major scientific breakthroughs in sequencing human genomes and the genomes of crops, animals and microbes. BGI makes state-of-the-art genomics highly accessible to the global research community and clinical fields. It does so by integrating the industry’s broadest array of technologies, including the BGISEQ platform, with economies of scale and expert bioinformatics resources.
“UW Medicine and BGI share the same goal to improve the health of the public,” said Dr. Yiwu He, global head of research and development at BGI. “Through our partnership, efforts and resources will be joined to produce more innovative healthcare solutions in precision medicine that will lead to more effective treatments available to patients. Advanced technologies and knowledge will also become more accessible to professionals and the public due to this partnership.”
BGI President Dr. Jian Wang, said, “As an alumnus of UW, I am really excited about the stronger tie BGI and UW have formed.”
He added, “With the commitment of UW Medicine and BGI, more innovations in research, education and healthcare will be developed between Seattle and Shenzhen to benefit the health of people worldwide.”
According to the agreement, UW Medicine and BGI will collaborate on the development of a joint Seattle-Shenzhen institute that will involve research institutions in each city including, but not necessarily limited to, UW and BGI.
“BGI is a respected partner in scientific discovery. This new relationship will help fast-track genomic research in some critical areas of medicine,” said Dr. John Slattery, vice dean for research and graduate education at UW Medicine.
“We at the UW are looking forward to working alongside BGI in charting the future of genomics research, especially in accelerating the application of new sequencing technologies to human health,” said Dr. Jay Shendure, an M.D./Ph.D scientist and professor of genome sciences at the UW, and a national advisor on precision medicine initiatives.